Judge: Bristol-Myers patent doesn't hold up under scrutiny

02/13/2013 | Pharmalot.com

A federal judge ruled that Bristol-Myers Squibb's patent on hepatitis B drug Baraclude is invalid because there is nothing unique about the drug's composition. The ruling, if it stands, clears the way for FDA approval of Teva Pharmaceutical Industries' generic version.

View Full Article in:


Published in Brief: